GILEAD SCIENCES, INC.

FOSTER CITY, CA · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 6, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$1.46B2026 Q3
Positions5
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.100.0%

GILEAD SCIENCES, INC. reported 5 positions worth $1.46B as of September 30, 2026 (13F filed November 6, 2026). Largest holding: RCUS (55.5%).

5 positions shown
#SymbolCompanyValue ↓% Port.Shares1YYTDSince reported
▸ 1 RCUSArcus Biosciences$811.7M55.45%31,424,760——-32.5%
▸ 2 LKFTLakefront Biotherapeutics$501.3M34.24%16,707,477——+17.3%
▸ 3 ASMBAssembly Biosciences$116.9M7.99%4,977,089——-9.4%
▸ 4 KYTXKyverna Therapeutics$28.1M1.92%4,126,119———
▸ 5Xilio Therape…Xilio Therapeutics$5.9M0.40%650,389———

Read the 2026-Q2 quarterly report · 13F Filing Calendar

🔔 Tell me when this fund files a new 13F

No account needed: in your inbox the morning it is published.

Frequently Asked Questions

What stocks does GILEAD SCIENCES, INC. hold as of Q3 2026?

GILEAD SCIENCES, INC. reported 5 positions worth $1.46B in its Q3 2026 13F filing. Largest positions: RCUS (55.5%), LKFT (34.2%), ASMB (8.0%), KYTX (1.9%) and Xilio Therapeutics Inc. (0.4%).

What did GILEAD SCIENCES, INC. buy in Q3 2026?

GILEAD SCIENCES, INC. opened or added to no positions in Q3 2026.

What did GILEAD SCIENCES, INC. sell in Q3 2026?

GILEAD SCIENCES, INC. reduced or sold out of no positions in Q3 2026.

13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.